NI201100007A - Compuestos químicos 251. - Google Patents
Compuestos químicos 251.Info
- Publication number
- NI201100007A NI201100007A NI201100007A NI201100007A NI201100007A NI 201100007 A NI201100007 A NI 201100007A NI 201100007 A NI201100007 A NI 201100007A NI 201100007 A NI201100007 A NI 201100007A NI 201100007 A NI201100007 A NI 201100007A
- Authority
- NI
- Nicaragua
- Prior art keywords
- pim
- chemical compounds
- relates
- kinase
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
La invención se refiere a compuestos químicos de fórmula I, y sales de los mismos. En algunas realizaciones, la invención se refiere a inhibidores o moduladores de la actividad o función enzimática de la proteína quinasa PIM-1 y/o PIM-2 y/o PIM-3. En otras realizaciones adicionales, la invención se refiere a composiciones farmacéuticas que comprenden compuestos descritos en la presente y su uso en la prevención y tratamiento de afecciones y enfermedades relacionadas con la quinasa PIM, preferiblemente cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7763908P | 2008-07-02 | 2008-07-02 | |
| US18327809P | 2009-06-02 | 2009-06-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201100007A true NI201100007A (es) | 2011-12-15 |
Family
ID=41050276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201100007A NI201100007A (es) | 2008-07-02 | 2011-01-05 | Compuestos químicos 251. |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8901307B2 (es) |
| EP (1) | EP2310010A2 (es) |
| JP (2) | JP5261575B2 (es) |
| KR (1) | KR20110031367A (es) |
| CN (2) | CN102137666B (es) |
| AR (1) | AR072791A1 (es) |
| AU (1) | AU2009265362B2 (es) |
| BR (1) | BRPI0914599A2 (es) |
| CA (1) | CA2729557A1 (es) |
| CL (1) | CL2010001636A1 (es) |
| CO (1) | CO6341555A2 (es) |
| CR (1) | CR20110016A (es) |
| DO (1) | DOP2010000408A (es) |
| EA (1) | EA018989B1 (es) |
| EC (1) | ECSP10010735A (es) |
| HN (1) | HN2010002786A (es) |
| IL (1) | IL210127A0 (es) |
| MX (1) | MX2010014233A (es) |
| MY (1) | MY155961A (es) |
| NI (1) | NI201100007A (es) |
| NZ (1) | NZ590859A (es) |
| PE (1) | PE20120304A1 (es) |
| SV (1) | SV2011003786A (es) |
| TW (1) | TWI461423B (es) |
| UY (1) | UY31952A (es) |
| WO (1) | WO2010001169A2 (es) |
| ZA (1) | ZA201100844B (es) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3184526T (pt) | 2005-12-13 | 2018-12-19 | Incyte Holdings Corp | Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus |
| US20080312259A1 (en) | 2007-06-13 | 2008-12-18 | Incyte Corporation | SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE |
| UY31952A (es) * | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
| ES2487542T3 (es) | 2009-05-22 | 2014-08-21 | Incyte Corporation | Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus |
| CN106967070A (zh) | 2009-05-22 | 2017-07-21 | 因塞特控股公司 | 作为jak抑制剂的化合物 |
| AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
| TWI766281B (zh) | 2010-03-10 | 2022-06-01 | 美商英塞特控股公司 | 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物 |
| PE20130216A1 (es) | 2010-05-21 | 2013-02-27 | Incyte Corp | Formulacion topica para un inhibidor de jak |
| JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
| AR083933A1 (es) | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| EA201490042A1 (ru) | 2011-06-20 | 2014-10-30 | Инсайт Корпорейшн | Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| JP6057907B2 (ja) * | 2011-10-04 | 2017-01-11 | 株式会社ヤクルト本社 | チアゾリジン誘導体又はその塩を有効成分とする医薬品 |
| WO2013146932A1 (ja) * | 2012-03-30 | 2013-10-03 | ロート製薬株式会社 | 新規ベンジリデンアゾリジン誘導体またはその塩 |
| AR091079A1 (es) | 2012-05-18 | 2014-12-30 | Incyte Corp | Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| EP2871179A4 (en) | 2012-07-03 | 2016-03-16 | Ono Pharmaceutical Co | CONNECTION WITH AGONISTIC EFFECT ON THE SOMATOSTATIN RECEPTOR AND ITS USE FOR MEDICAL PURPOSES |
| SG11201503695XA (en) | 2012-11-15 | 2015-06-29 | Incyte Corp | Sustained-release dosage forms of ruxolitinib |
| JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
| NZ710079A (en) | 2013-01-15 | 2020-01-31 | Incyte Holdings Corp | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
| HUE057262T2 (hu) | 2013-03-06 | 2022-04-28 | Incyte Holdings Corp | Eljárás és köztitermékek JAK inhibitor elõállítására |
| JP6378918B2 (ja) * | 2013-04-03 | 2018-08-22 | 株式会社ヤクルト本社 | チアゾリジン誘導体又はその塩を有効成分とするＰｉｍ阻害剤 |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| US9655854B2 (en) | 2013-08-07 | 2017-05-23 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
| AR097431A1 (es) | 2013-08-23 | 2016-03-16 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim |
| JP5799148B2 (ja) * | 2013-09-27 | 2015-10-21 | ロート製薬株式会社 | 新規ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物 |
| TW201601763A (zh) * | 2013-09-27 | 2016-01-16 | 樂敦製藥股份有限公司 | 皮膚外用組成物 |
| WO2015122504A1 (ja) * | 2014-02-13 | 2015-08-20 | 国立大学法人 東京大学 | キナーゼ阻害剤 |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| JP5857104B2 (ja) * | 2014-06-17 | 2016-02-10 | ロート製薬株式会社 | ベンジリデンアゾリジン誘導体またはその塩を含む皮膚外用組成物 |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US10195189B2 (en) | 2014-12-15 | 2019-02-05 | Prosetta Antiviral, Inc. | 2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds |
| CN105985298B (zh) * | 2015-02-10 | 2018-02-23 | 湖南大学 | 2‑[(5‑卤噻唑‑2‑基)亚氨基]‑5‑亚苄基噻唑啉酮及其制备方法与应用 |
| WO2016144635A1 (en) | 2015-03-06 | 2016-09-15 | Beyondspring Pharmaceuticals, Inc. | Method of treating cancer associated with a ras mutation |
| CN106032365B (zh) * | 2015-03-11 | 2018-03-23 | 湖南大学 | 2‑(噻唑‑2‑基)亚氨基‑5‑亚苄基噻唑啉酮及其制备方法与应用 |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| MY181892A (en) | 2015-07-13 | 2021-01-12 | Beyondspring Pharmaceuticals Inc | Plinabulin compositions |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| SG11201806583XA (en) | 2016-02-08 | 2018-09-27 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs |
| DK3439667T3 (da) | 2016-04-05 | 2024-04-02 | Immune Sensor Llc | Cgas antagonist forbindelser |
| AU2017278245B2 (en) | 2016-06-06 | 2022-09-15 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing neutropenia |
| SG11201809559UA (en) | 2016-06-13 | 2018-12-28 | Glaxosmithkline Ip Dev Ltd | Substituted pyridines as inhibitors of dnmt1 |
| US11633393B2 (en) | 2017-01-06 | 2023-04-25 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| MY201811A (en) | 2017-02-01 | 2024-03-19 | Beyondspring Pharmaceuticals Inc | Method of reducing neutropenia |
| US11319320B2 (en) | 2017-11-06 | 2022-05-03 | Snap Bio, Inc. | PIM kinase inhibitor compositions, methods, and uses thereof |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| SG11202006985TA (en) | 2018-01-24 | 2020-08-28 | Beyondspring Pharmaceuticals Inc | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
| CN112105608B (zh) | 2018-01-30 | 2023-07-14 | 因赛特公司 | 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法 |
| AU2019245420A1 (en) | 2018-03-30 | 2020-11-12 | Incyte Corporation | Treatment of hidradenitis suppurativa using JAK inhibitors |
| KR102308134B1 (ko) * | 2018-04-26 | 2021-10-01 | 재단법인 의약바이오컨버젼스연구단 | mTOR 저해제로서의 신규 화합물 및 이의 용도 |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| WO2023039170A1 (en) * | 2021-09-09 | 2023-03-16 | Musc Foundation For Research Development | Selective targeting of cd38 activity as an immunostimulatory and antitumor strategy |
| CN116354901B (zh) * | 2023-04-12 | 2024-04-26 | 郑州大学 | 一种噻唑烷二酮类化合物及其制备方法和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE62214B1 (en) * | 1988-05-25 | 1995-01-11 | Warner Lambert Co | Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents |
| CZ289317B6 (cs) * | 1994-04-11 | 2002-01-16 | Sankyo Company Limited | Heterocyklická sloučenina, farmaceutický prostředek ji obsahující a její pouľití |
| JP3668291B2 (ja) * | 1995-06-16 | 2005-07-06 | 久光製薬株式会社 | 新規なピペリジン誘導体 |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| EP0880508B1 (en) | 1996-02-13 | 2003-04-16 | AstraZeneca AB | Quinazoline derivatives as vegf inhibitors |
| ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| UA56185C2 (uk) | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
| TW577875B (en) * | 1997-01-31 | 2004-03-01 | Shionogi & Co | Pyrrolidine derivatives with inhibitory activity for phospholipase A2 |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| ID29875A (id) * | 1999-07-01 | 2001-10-18 | Geron Corp Cs | Penghambat-penghambat telomerase dan metode penggunaannya |
| TW593293B (en) * | 1999-08-23 | 2004-06-21 | Kyorin Seiyaku Kk | Substituted benzylthiazolidine-2,4-dione derivatives |
| US6730687B1 (en) | 1999-08-23 | 2004-05-04 | Kyorin Pharmaceutical Co., Ltd. | Substituted benzylthiazolidine-2, 4-dione derivatives |
| AU1595001A (en) * | 1999-11-11 | 2001-06-06 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| KR20030013433A (ko) | 2000-05-31 | 2003-02-14 | 아스트라제네카 아베 | 혈관 손상 활성을 가진 인돌 유도체 |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| AU6623301A (en) | 2000-07-07 | 2002-01-21 | Angiogene Pharm Ltd | Colchinol derivatives as vascular damaging agents |
| US6452014B1 (en) * | 2000-12-22 | 2002-09-17 | Geron Corporation | Telomerase inhibitors and methods of their use |
| BR0312752A (pt) | 2002-07-10 | 2005-04-26 | Applied Research Systems | Derivados de benzeno fundido de azolidinona-vinil |
| AU2004232326A1 (en) * | 2003-04-18 | 2004-11-04 | Incyte San Diego Incorporated | Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases |
| ATE464303T1 (de) | 2004-04-28 | 2010-04-15 | Vertex Pharma | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen |
| US7714005B2 (en) * | 2004-12-22 | 2010-05-11 | The Ohio State University Research Foundation | Small molecule Bcl-xL/Bcl-2 binding inhibitors |
| US20110263664A1 (en) * | 2007-11-15 | 2011-10-27 | Musc Foundation For Research Development | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer |
| UY31952A (es) * | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
-
2009
- 2009-07-01 UY UY0001031952A patent/UY31952A/es not_active Application Discontinuation
- 2009-07-01 TW TW098122261A patent/TWI461423B/zh not_active IP Right Cessation
- 2009-07-02 MX MX2010014233A patent/MX2010014233A/es active IP Right Grant
- 2009-07-02 PE PE2010001221A patent/PE20120304A1/es not_active Application Discontinuation
- 2009-07-02 EA EA201100119A patent/EA018989B1/ru not_active IP Right Cessation
- 2009-07-02 CA CA2729557A patent/CA2729557A1/en not_active Abandoned
- 2009-07-02 BR BRPI0914599A patent/BRPI0914599A2/pt not_active IP Right Cessation
- 2009-07-02 CN CN200980134849.5A patent/CN102137666B/zh not_active Expired - Fee Related
- 2009-07-02 CN CN201410037508.9A patent/CN103804371A/zh active Pending
- 2009-07-02 EP EP09772849A patent/EP2310010A2/en not_active Withdrawn
- 2009-07-02 MY MYPI2010006322A patent/MY155961A/en unknown
- 2009-07-02 JP JP2011515631A patent/JP5261575B2/ja not_active Expired - Fee Related
- 2009-07-02 NZ NZ590859A patent/NZ590859A/xx not_active IP Right Cessation
- 2009-07-02 AR ARP090102486A patent/AR072791A1/es unknown
- 2009-07-02 AU AU2009265362A patent/AU2009265362B2/en not_active Ceased
- 2009-07-02 WO PCT/GB2009/050773 patent/WO2010001169A2/en active Application Filing
- 2009-07-02 KR KR1020117002754A patent/KR20110031367A/ko not_active Application Discontinuation
- 2009-07-02 US US13/000,138 patent/US8901307B2/en not_active Expired - Fee Related
-
2010
- 2010-12-20 IL IL210127A patent/IL210127A0/en unknown
- 2010-12-30 EC EC2010010735A patent/ECSP10010735A/es unknown
- 2010-12-30 CL CL2010001636A patent/CL2010001636A1/es unknown
- 2010-12-30 HN HN2010002786A patent/HN2010002786A/es unknown
- 2010-12-30 DO DO2010000408A patent/DOP2010000408A/es unknown
-
2011
- 2011-01-03 SV SV2011003786A patent/SV2011003786A/es unknown
- 2011-01-05 NI NI201100007A patent/NI201100007A/es unknown
- 2011-01-10 CR CR20110016A patent/CR20110016A/es unknown
- 2011-02-01 CO CO11011427A patent/CO6341555A2/es active IP Right Grant
- 2011-02-01 ZA ZA2011/00844A patent/ZA201100844B/en unknown
-
2013
- 2013-02-20 JP JP2013031176A patent/JP2013139459A/ja not_active Ceased
-
2014
- 2014-07-24 US US14/339,981 patent/US20150051185A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201100007A (es) | Compuestos químicos 251. | |
| AU2011338389A8 (en) | Bicyclic compounds as Pim inhibitors | |
| BRPI0712816B8 (pt) | compostos de pirrolpirimidina e seus usos | |
| ECSP088152A (es) | 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización | |
| CL2009000967A1 (es) | Compuesto 4-ciclobutil-n-((2s,5r)-5-hidroxi-2-adamantil)-2-morfolin-4-ilpiridin-5-carboxamida, inhibidor de la enzima 11betahsd1; composicion farmaceutica que lo comprende; y su uso en un procedimiento de tratamiento profilactico o terapeutico de un animal de sangre caliente. | |
| BRPI0719195B8 (pt) | inibidores de quinase, seus usos, e composição farmacêutica | |
| ECSP10010310A (es) | Nuevos compuestos y composiciones y métodos de uso | |
| GT200800184A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes. | |
| UY32302A (es) | Carboxamidas heterobicíclicas como inhibidoras de cinasas | |
| EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
| BRPI0721905B8 (pt) | composto inibidor de proteassoma, sua composição farmacêutica e seu uso | |
| EA201101341A1 (ru) | Соединения, ингибирующие киназы, и фармацевтическая композиция на их основе | |
| UY29853A1 (es) | Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas- | |
| ECSP077324A (es) | Amidas bicíclicas como inhibidores de cinasa | |
| MX2013012661A (es) | Compuestos de piridazina biciclicos como inhibidores pim. | |
| ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| ECSP099776A (es) | Moduladores de la gamma secretasa | |
| MX2009004623A (es) | Imidazopiridazinas como inhibidores de la lipido cinasa pi3k. | |
| GT200800206A (es) | Dimeros de derivados de artemisinina, su preparacion y su aplicacion en terapeutica | |
| ECSP088252A (es) | 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización | |
| CU20100032A7 (es) | Depsipéptidos cíclicos | |
| UY29358A1 (es) | Tiazolidinonas, su preparacion y su uso como medicamento | |
| HN2011000404A (es) | Derivados de enfumafungina y composicion comprendiendo los mismos | |
| UY31146A1 (es) | Derivado de 17b-ciano-19-nor-androst-4-eno, su uso y medicamento que lo contiene | |
| BRPI0520806A2 (pt) | derivados pirrólicos, processos para a preparação de compostos, seu uso e composição farmacêutica que os contém |